Orasure Technologies Inc transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. The company focuses on the development manufacture marketing sale and distribution of diagnostics products and sample management solutions. Its diagnostics portfolio includes rapid point of care tests for infectious diseases such as HIV hepatitis C syphilis sickle cell and COVID 19. The company also offers sample management products that enable collection stabilization transportation and storage of biological specimens for genomics proteomics microbiome and other applications. In November 2025 it acquired BioMedomics Inc adding the SickleSCAN test the world’s first rapid point of care test for sickle cell disease to its offerings. The company’s integrated approach combines commercial and innovation teams within a single business unit to streamline product development and market access. This structure enables rapid translation of laboratory discoveries into commercially available diagnostics. In addition to organic growth Orasure Technologies Inc pursues strategic acquisitions to broaden its product pipeline and geographic reach. The acquisition of BioMedomics exemplifies this strategy by bringing a novel sickle cell test to the portfolio.

Revenue is generated primarily from the sale of diagnostic test kits and related instruments as well as from sample collection devices and associated services. Diagnostic sales come from hospitals clinics public health organizations laboratories distributors and direct to consumer channels including over the counter retail. Sample management revenue stems from sales to academic research institutions pharmaceutical biotech companies and contract testing laboratories that use the products for genetic proteomic and microbiome workflows. The company also earns income from licensing arrangements and collaborative development agreements. A portion of sales is derived from repeat customers who replenish inventory on a regular basis. Revenue from diagnostic tests is driven by volume sales of test kits and repeat purchases from public health programs that require regular screening. Over the counter sales contribute a growing share particularly for HIV and COVID 19 self test kits sold via major retailers and online platforms. Sample management revenue benefits from long term supply agreements with large genomics service providers and from niche markets such as microbiome research where specialized collection commands premium pricing. The company also generates income from contract manufacturing services for third parties who need proprietary collection devices.

The company operates through the following segments.

• The Diagnostics segment develops manufactures and markets rapid immunoassay and molecular tests that detect antibodies antigens or nucleic acids from oral fluid blood or urine. Key products include the OraQuick HIV test the OraQuick HCV test the OraQuick HIV self test the OraQuick HCV self test the Inteliswab COVID 19 test and the SickleSCAN sickle cell test. These tests are designed for use in clinical labs point of care settings and at home and many have received FDA clearance CLIA waiver status or World Health Organization prequalification. The segment also offers OTC versions that are sold through retailers and online platforms to consumers seeking private test. The segment invests heavily in research and development to improve test sensitivity specificity and time to result. It also pursues regulatory pathways such as De Novo classification and premarket approval to expand indications for existing platforms. Manufacturing is concentrated in the company’s Bethlehem Pennsylvania facility with select overseas assembly to meet international demand. Distribution combines direct sales teams for institutional customers and a network of independent distributors for broader market coverage.

• The Sample Management Solutions segment provides devices that collect stabilize transport and store DNA RNA proteins metabolites and other biomolecules. Core offerings are the Oragene and ORAcollect saliva collection kits the Colli Pee urine collection device the HEMAcollect protein stabilization tube and the OMNIGene line for microbiome sampling. These products serve genomics proteomics microbiome and infectious disease research and are sold to academic labs commercial service providers and contract research organizations. The segment also supports emerging areas such as liquid biopsy and companion animal health through specialized collection systems. Research and development in this segment focuses on improving sample stability at ambient temperature and extending the shelf life of collected specimens. New product initiatives include devices for cell free RNA extraction and for preserving proteins in blood samples for proteomic studies. The segment leverages the company’s global sales force to reach academic core facilities and large contract research organizations. Technical support and training programs are provided to ensure proper use of collection kits in diverse laboratory environments.

The diagnostic industry is highly fragmented with many participants ranging from large multinational corporations to small niche players. Orasure Technologies Inc competes against firms that have greater financial resources but differentiates itself through proprietary technology that emphasizes ease of use and rapid results. The company’s products often feature CLIA waived status and FDA clearance which allow them to be used in a broad range of settings including non traditional sites such as outreach clinics and home environments. Regulatory achievements such as World Health Organization prequalification and CE marking provide access to international markets and public health funding streams. The firm also benefits from a strong patent portfolio that protects its sampling technologies and assay formats. Competitive advantages stem from the company’s proprietary chemistries that stabilize nucleic acids and proteins without refrigeration. The ease of use of its oral fluid and urine collection devices reduces the need for trained phlebotomy personnel. Strong regulatory track record including multiple FDA clearances and WHO prequalifications builds trust with procurement agencies. Additionally the firm’s patent estate creates barriers to entry for competitors attempting to replicate its sample stabilization technology.

The company serves a diverse set of customers that includes hospital laboratories public health agencies community based organizations physician offices and clinics. Diagnostic products are also sold through distributors to retail chains and sold directly to consumers in over the counter markets. Sample management solutions are purchased by academic research institutions pharmaceutical biotech companies contract testing laboratories and companies involved in livestock and companion animal health. Notable customers mentioned in the filing include major pharmacy chains and government health programs although specific names are not disclosed. The firm maintains relationships with repeat buyers who account for a significant portion of recurring revenue. In the diagnostic business key customers include state and local health departments that purchase HIV and hepatitis C tests for community outreach programs. Hospitals and urgent care clinics utilize the COVID 19 antigen tests for rapid patient triage. Retail pharmacies stock the over the counter self test kits to meet consumer demand for private testing. In the sample management arena major genomics companies such as those offering direct to consumer ancestry tests rely on Oragene kits for saliva collection. Contract research organizations use the Colli Pee device for urine based biomarker studies in oncology and infectious disease trials. The company also serves veterinary laboratories that need specialized collection tools for livestock disease surveillance.